Mizuho downgraded Karuna Therapeutics (KRTX) to Neutral from Buy with a price target of $330, up from $245. The firm finds it unlikely that a superior takeover offer will emerge. As such, the Bristol Myers (BMY) transaction as initially proposed will pass regulatory review and successfully close during the first half of 2024, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRTX:
- The biopharmaceuticals stocks to own in 2024, according to BofA
- Bristol Myers downgraded to Neutral at BofA as more clarity on execution awaited
- Karuna Therapeutics price target raised to $330 from $197 at UBS
- Karuna Therapeutics downgraded to Neutral from Overweight at JPMorgan
- RayzeBio deal another ‘incremental positive’ for Bristol, says Morgan Stanley